Literature DB >> 17541610

WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?

Matthias Mehling1, Perikles Simon, Michel Mittelbronn, Richard Meyermann, Soldano Ferrone, Michael Weller, Heinz Wiendl.   

Abstract

Defects of major histocompatibility complex (MHC) class I antigen-processing machinery (APM) components have been shown to contribute to immune escape of malignant cells. We investigated the expression of APM components in astrocytomas without detectable defects in HLA class I antigen expression and correlated it with grade of malignancy. Quantitative immunohistochemical analysis of astrocytomas revealed reduced expression of the cytosolic proteasome subunit low molecular weight protein 2 (LMP2), the endoplasmatic reticulum (ER) transporter associated with antigen processing-1 (TAP1), and the ER chaperone beta2-microglobulin (beta2m) in astrocytoma cells when compared to astrocytes from nonpathological brain. Among human WHO grade II-IV astrocytomas, downregulation of LMP2, TAP1 and beta2m correlated with grade of malignancy. Furthermore, astrocytoma cell lines (n = 12) expressed all APM components analyzed at levels comparable to dendritic cells (DC), which were used for comparative purposes. However, upregulation of beta2m after stimulation with inflammatory cytokines was significantly lower in astrocytoma cell lines than in control cells. Our results support the hypothesis that coordinated downregulation or impaired upregulation of certain HLA class I APM components may serve as a mechanism for astrocytoma cells to evade the host's immune response, even if HLA class I antigen surface expression is not altered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541610     DOI: 10.1007/s00401-007-0231-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  23 in total

1.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

2.  MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma.

Authors:  Alessandra Favole; Paolo Cascio; Fulvia Cerruti; Alessandra Sereno; Massimiliano Tursi; Alessandro Tomatis; Cristina Della Beffa; Soldano Ferrone; Enrico Bollo
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

Review 3.  Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?

Authors:  Sylvia C Kurz; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2018-04-18       Impact factor: 3.598

Review 4.  Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.

Authors:  Joanna Y Wang; Chetan Bettegowda
Journal:  J Neurooncol       Date:  2015-02-21       Impact factor: 4.130

5.  Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.

Authors:  Orin Bloch; Courtney A Crane; Rajwant Kaur; Michael Safaee; Martin J Rutkowski; Andrew T Parsa
Journal:  Clin Cancer Res       Date:  2013-04-23       Impact factor: 12.531

Review 6.  Overview of current immunotherapeutic strategies for glioma.

Authors:  Anda-Alexandra Calinescu; Neha Kamran; Gregory Baker; Yohei Mineharu; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

7.  Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study.

Authors:  Isabela J Wastowski; Renata T Simões; Layale Yaghi; Eduardo A Donadi; João T Pancoto; Isabelle Poras; Emmanuèle Lechapt-Zalcman; Myriam Bernaudin; Samuel Valable; Carlos G Carlotti; Sébastien Flajollet; Stine S Jensen; Soldano Ferrone; Edgardo D Carosella; Bjarne W Kristensen; Philippe Moreau
Journal:  Am J Pathol       Date:  2012-12-04       Impact factor: 4.307

8.  Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer.

Authors:  Jung-hyun Rho; Shuzhen Qin; Julia Y Wang; Michael H A Roehrl
Journal:  J Proteome Res       Date:  2008-06-13       Impact factor: 4.466

Review 9.  Vaccine therapies for patients with glioblastoma.

Authors:  Eli T Sayegh; Taemin Oh; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2014-08-28       Impact factor: 4.130

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.